Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

SARS vaccine development.

Shibo Jiang1, Yuxian He, Shuwen Liu

  • 1New York Blood Center, New York, New York 10021, USA. SJiang@NYBloodcenter.org

Emerging Infectious Diseases
|July 19, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Analogous comparison unravels heightened antiviral defense and boosted viral infection upon immunosuppression in bat organoids.

Signal transduction and targeted therapy·2022
Same author

Sertraline Is an Effective SARS-CoV-2 Entry Inhibitor Targeting the Spike Protein.

Journal of virology·2022
Same author

Correction: A Truncated Receptor-Binding Domain of MERS-CoV Spike Protein Potently Inhibits MERS-CoV Infection and Induces Strong Neutralizing Antibody Responses: Implication for Developing Therapeutics and Vaccines.

PloS one·2022
Same author

A variant-proof SARS-CoV-2 vaccine targeting HR1 domain in S2 subunit of spike protein.

Cell research·2022
Same author

Neutralization of five SARS-CoV-2 variants of concern by convalescent and BBIBP-CorV vaccinee serum.

Virologica Sinica·2022
Same author

FBXO34 promotes latent HIV-1 activation by post-transcriptional modulation.

Emerging microbes & infections·2022

Developing safe and effective severe acute respiratory syndrome (SARS) vaccines is critical. Research suggests using the SARS-associated coronavirus (SARS-CoV) receptor-binding domain (RBD) in recombinant vaccines offers a promising approach.

Area of Science:

  • Virology
  • Immunology
  • Vaccine Development

Background:

  • Severe acute respiratory syndrome (SARS) outbreaks necessitate urgent development of effective and safe vaccines.
  • Inactivated SARS-associated coronavirus (SARS-CoV) vaccines are feasible but raise safety concerns.
  • The SARS-CoV spike (S) protein, particularly the receptor-binding domain (RBD), is key for inducing neutralizing antibodies.

Purpose of the Study:

  • To explore the potential of recombinant proteins and vectors encoding the RBD for developing safe and effective SARS vaccines.
  • To identify alternative vaccine strategies beyond inactivated SARS-CoV vaccines.

Main Methods:

  • Analysis of the SARS-CoV spike protein structure and function.
  • Review of existing research on neutralizing epitopes and antibody induction.

Related Experiment Videos

  • Conceptualization of recombinant protein and vector-based vaccine approaches.

    • Main Results:

    • The receptor-binding domain (RBD) of the SARS-CoV spike protein contains critical neutralizing epitopes.
    • Recombinant proteins incorporating the RBD can elicit neutralizing antibodies.
    • Gene vectors encoding the RBD sequence offer a platform for vaccine development.

    Conclusions:

    • Recombinant vaccines utilizing the SARS-CoV RBD present a potentially safer and effective alternative to inactivated vaccines.
    • Targeting the RBD is a promising strategy for developing SARS vaccines.
    • Further research into RBD-based vaccines is warranted for SARS prevention.